MedPath

Diltiazem

Generic Name
Diltiazem
Brand Names
Cardizem, Cartia, Matzim, Taztia, Tiadylt, Tiazac
Drug Type
Small Molecule
Chemical Formula
C22H26N2O4S
CAS Number
42399-41-7
Unique Ingredient Identifier
EE92BBP03H
Background

Diltiazem is a benzothiazepine derivative with antihypertensive and vasodilating properties. Approved in 1982 by the FDA, it is a member of the non-dihydropyridine calcium channel blockers drug class. It works through various mechanisms of action, but it primarily works by inhibiting the calcium influx into cardiac and vascular smooth muscle during depolarization. Compared to dihydropyridine drugs, such as nifedipine, that preferentially act on vascular smooth muscle and verapamil that directly acts on the heart muscle, diltiazem displays an intermediate specificity to target both the cardiac and vascular smooth muscle. Being a potent vasodilator, diltiazem is used clinically as an antihypertensive, anti-arrhythmic, and as an anti-anginal agent for the management of cardiovascular conditions such as hypertension, chronic stable angina, atrial fibrillation, atrial flutter. Apart from its main FDA-approved indications, diltiazem has also been used for numerous off-label indications, such as anal fissures (in topical formulations), migraine prophylaxis, pulmonary hypertension, and rest-related cramps in the lower extremities. Typically available in extended-release oral and intravenous formulations, diltiazem is marketed under various brand names with Cardizem and Tiazac being the most common ones.

Indication

Oral

Indicated for the management of hypertension, to lower blood pressure, alone or in combination with other antihypertensive agents.

Indicated for use to improve exercise tolerance in patients with chronic stable angina.

Indicated for the management of variant angina (Prinzmetal's angina).

Intravenous

Indicated for the short-term management of atrial fibrillation or atrial flutter for temporary control of rapid ventricular rate.

Indicated for the rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. This includes AV nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the WPW syndrome or short PR syndrome.

Off-label

Indicated for off-label uses in anal fissures (as topical formulation), migraine prophylaxis, cramps in lower leg related to rest, pulmonary hypertension, idiopathic dilated cardiomyopathy, and proteinuria associated with diabetic nephropathy.

Associated Conditions
Angina Pectoris, Variant, Anginal Pain, Atrial Fibrillation, Atrial Flutter, Chronic Stable Angina Pectoris, Dilated Cardiomyopathies, Idiopathic, Fissure;Anal, Hypertension, Paroxysmal Supraventricular Tachycardia (PSVT), Proteinuria, Pulmonary Hypertension (PH), Leg cramps, Prophylaxis of migraine headaches

A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose of Danicamtiv in Healthy Participants

Phase 1
Completed
Conditions
Healthy Participants
Interventions
First Posted Date
2021-12-17
Last Posted Date
2022-08-10
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
30
Registration Number
NCT05162222
Locations
🇺🇸

Covance Clinical Research Unit - Dallas, Dallas, Texas, United States

Efficacy of Oral Verapamil and Oral Diltiazim on Reduction of Intraoperative Bleeding During Endoscopic Sinus Surgery Under General Anesthesia

Early Phase 1
Conditions
Verapamil
Diltiazim
FESS
Interventions
First Posted Date
2021-03-10
Last Posted Date
2021-03-10
Lead Sponsor
Assiut University
Target Recruit Count
135
Registration Number
NCT04790331

Efficacy of Diltiazem to Improve Coronary Microvascular Dysfunction: a Randomized Clinical Trial

Phase 3
Active, not recruiting
Conditions
Microvascular Ischemia of Myocardium
Microvascular Angina
Coronary Vasospasm
Interventions
First Posted Date
2021-03-02
Last Posted Date
2023-03-30
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
85
Registration Number
NCT04777045
Locations
🇳🇱

Maasstad Hospital, Rotterdam, Netherlands

🇳🇱

Radboud University Medical Center, Nijmegen, Gelderland, Netherlands

🇳🇱

Catharina Hospital, Eindhoven, Netherlands

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

First Posted Date
2020-09-16
Last Posted Date
2024-10-26
Lead Sponsor
BeiGene
Target Recruit Count
26
Registration Number
NCT04551963
Locations
🇦🇺

Concord Repatriation General Hospital, Concord, New South Wales, Australia

🇦🇺

John Flynn Private Hospital, Tugun, Queensland, Australia

🇦🇺

Royal Adelaide Hospital, Adelaide, South Australia, Australia

and more 4 locations

Different Anti-Spastic Therapy Strategies After CABG Using Radial Artery Grafts

Phase 4
Completed
Conditions
Antispastic Therapy
Coronary Artery Bypass Graft
Radial Artery Grafts
Pilot Study
Interventions
First Posted Date
2020-03-17
Last Posted Date
2024-12-12
Lead Sponsor
Ruijin Hospital
Target Recruit Count
150
Registration Number
NCT04310995
Locations
🇨🇳

Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China

Efficacy of Diltiazem for the Control of Blood Pressure in Puerperal Patients With Severe Preeclampsia

Not Applicable
Completed
Conditions
Postpartum Preeclampsia
Interventions
First Posted Date
2020-01-10
Last Posted Date
2020-01-10
Lead Sponsor
Hospital de la Mujer
Target Recruit Count
42
Registration Number
NCT04222855

A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy Participants

Phase 1
Completed
Conditions
Health Participants
Interventions
First Posted Date
2019-11-07
Last Posted Date
2022-01-04
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
114
Registration Number
NCT04154800
Locations
🇺🇸

PPD Development, LP, Austin, Texas, United States

Comparative Evaluation of MEBO Ointment and Topical Diltiazem Ointment in the Treatment of Acute Anal Fissure

Phase 2
Recruiting
Conditions
Anal Fissure
Interventions
Drug: Mebo
First Posted Date
2019-11-06
Last Posted Date
2025-01-29
Lead Sponsor
American University of Beirut Medical Center
Target Recruit Count
183
Registration Number
NCT04153032
Locations
🇱🇧

American University of Beirut, Beirut, Lebanon

Bolus vs IVP (Intravenous Push) Diltiazem for Atrial Fibrillation or Flutter

Phase 4
Conditions
Rapid Ventricular Response
Atrial Fibrillation
Atrial Flutter
Interventions
First Posted Date
2019-10-28
Last Posted Date
2019-10-28
Lead Sponsor
Mercy Health Muskegon
Target Recruit Count
300
Registration Number
NCT04141553

Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging

Phase 2
Terminated
Conditions
Myocardial Bridging
Interventions
First Posted Date
2019-10-17
Last Posted Date
2025-02-25
Lead Sponsor
Stanford University
Target Recruit Count
5
Registration Number
NCT04130438
Locations
🇺🇸

Stanford University, Stanford, California, United States

© Copyright 2025. All Rights Reserved by MedPath